Table 1.
Baseline Clinical Characteristics of the Study Participants
| Non-Lymphadenectomy Group (N = 117) | Lymphadenectomy Group (N = 121) | Total (N = 238) | P | |
|---|---|---|---|---|
| Age | 0.418 | |||
| <60 years | 95 (81.2%) | 103 (85.1%) | 198 (83.2%) | |
| ≥60 years | 22 (18.8%) | 18 (14.9%) | 40 (16.8%) | |
| Surgical method | <0.001 | |||
| Total abdominal hysterectomy | 74 (63.2%) | 108 (89.3%) | 182 (76.5%) | |
| Total laparoscopic hysterectomy | 43 (36.8%) | 13 (10.7%) | 56 (23.5%) | |
| Tumor size | 0.072 | |||
| <2 cm | 56 (47.9%) | 44 (36.4%) | 100 (42.0%) | |
| ≥2 cm | 61 (52.1%) | 77 (63.6%) | 138 (58.0%) | |
| Myometrial invasion§ | 1.000 | |||
| <50% | 115 (99.1%) | 119 (99.2%) | 234 (99.2%) | |
| ≥50% | 1 (0.9%) | 1 (0.8%) | 2 (0.8%) | |
| Histologic grade§ | <0.001 | |||
| Complex atypical hyperplasia | 1 (0.9%) | 1 (0.8%) | 2 (0.8%) | |
| 1 | 74 (63.2%) | 44 (36.4%) | 118 (49.6%) | |
| 2 | 42 (35.9%) | 76 (62.8%) | 118 (49.6%) | |
| Lymphovascular space invasion | 0.343 | |||
| Negative | 103 (88%) | 111 (91.7%) | 214 (89.9%) | |
| Positive | 14 (12%) | 10 (8.3%) | 24 (10.1%) | |
| Surgical-pathologic stage§ | 0.903 | |||
| Ia | 114 (97.4%) | 118 (97.5%) | 232 (97.5%) | |
| Ib | 1 (0.9%) | 1 (0.8%) | 2 (0.8%) | |
| II | 2 (1.7%) | 1 (0.8%) | 3 (1.3%) | |
| IIIb | 0 (0.0%) | 1 (0.8%) | 1 (0.4%) | |
| Postoperative treatment | 1.000 | |||
| Radiotherapy | 15 (12.8%) | 16 (13.2%) | 31 (13.0%) | |
| Chemoradiotherapy | 0 (0.0%) | 1 (0.8%) | 1 (0.8%) | |
| None | 102 (87.2%) | 104 (86.0%) | 206 (86.6%) |
Note: §Based on postoperative pathology.